<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097577</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20100004H</org_study_id>
    <nct_id>NCT01097577</nct_id>
  </id_info>
  <brief_title>A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery</brief_title>
  <official_title>A Comparison of Pregabalin (Lyrica®) to Placebo in Postoperative Pain Relief of Patients Status-post Photorefractive Keratectomy: A Double-masked Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilford Hall Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wilford Hall Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To compare the efficacy of pregabalin to placebo for postoperative pain control
      after photorefractive keratectomy.

      Patients: Study subjects will be taken from a standard group of typical candidates for PRK
      surgery including active duty and DoD beneficiaries. Prior to being approached for the study,
      all patients will have had a previous desire for surgery and had a pre-operative evaluation
      indicating healthy ocular status.

      Methods: Patients scheduled for PRK surgery will be briefed on the purpose of the study and
      invited to participate at the preoperative appointment. After the consent process, patients
      will be randomized in a 1:1 fashion to receive either oral pregabalin 75mg BID or placebo for
      pain control, in addition to the standard care treatment of as needed Percocet and tetracaine
      ophthalmic drops. Subjects will be evaluated daily for 4 days post-operatively for subjective
      pain assessment, adverse drug events and compliance, use of concomitant medications as well
      as monitoring of healing time. Quality of life will be measured at baseline and post-op day 2
      when the peak of pain is anticipated. Analysis will be performed to detect an approximate 10%
      improvement in pain scores. Secondary outcomes will include measuring healing time, quality
      of life and use of rescue medications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Efficacy</measure>
    <time_frame>5 days</time_frame>
    <description>Determine if clinical efficacy is achieved with pregabalin administered prior to PRK and continued for 5 days. This will be evaluated using the short-form McGill pain questionnaire (SF-MPQ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy 2</measure>
    <time_frame>5 days</time_frame>
    <description>Determine if there was a reduction in the need for use of rescue pain medications, Percocet and tetracaine, in those subjects who received pregabalin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epithelial healing time</measure>
    <time_frame>5 days or more</time_frame>
    <description>Determine if there was a reduction in healing time associated with pregabalin as seen with daily slit-lamp observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 days</time_frame>
    <description>Determine if there was an improvement in the patient's functional health and well-being associated with pregabalin compared to standard of care as assessed by Brief Pain Inventory-short form (BPI-SF).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>lactose capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
    <arm_group_label>pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.</description>
    <arm_group_label>lactose capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy ocular status

          -  Stable preoperative refractive anisometropia

          -  Consented to the PRK surgical procedure

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Diagnosed with autoimmune disease or diabetes

          -  Patients with a known adverse reaction or hypersensitivity to gabapentin or pregabalin

          -  Patients only desiring PRK on one eye

          -  Patients with history of drug use/abuse/addiction

          -  Patients who are on chronic pain medications

          -  Patients currently taking anti-epileptic, antidepressant and/or anti-psychotic
             medications

          -  Patients with a history of suicidality

          -  Patients with chronic renal insufficiency (defined as estimated creatinine clearance
             less than 30ml/min or Scr ≥ 2.0) 10) Patients who have experienced angioedema, or have
             heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie M Meek, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wilford Hall Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Reilly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wilford Hall Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret Bonnie Rosbolt, PharmD, CCRC</last_name>
    <role>Study Director</role>
    <affiliation>Wilford Hall Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilford Hall Medical Center - Refractive Surgery Center</name>
      <address>
        <city>Lackland AFB</city>
        <state>Texas</state>
        <zip>78236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>O'Doherty M, Kirwan C, O'Keeffe M, O'Doherty J. Postoperative pain following epi-LASIK, LASEK, and PRK for myopia. J Refract Surg. 2007 Feb;23(2):133-8.</citation>
    <PMID>17326352</PMID>
  </reference>
  <reference>
    <citation>Netto MV, Mohan RR, Ambrósio R Jr, Hutcheon AE, Zieske JD, Wilson SE. Wound healing in the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea. 2005 Jul;24(5):509-22. Review.</citation>
    <PMID>15968154</PMID>
  </reference>
  <reference>
    <citation>Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin--calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009 Mar;142(1-2):13-6. doi: 10.1016/j.pain.2008.11.019. Epub 2009 Jan 6. Review.</citation>
    <PMID>19128880</PMID>
  </reference>
  <reference>
    <citation>Guay DR. Pregabalin in neuropathic pain: a more &quot;pharmaceutically elegant&quot; gabapentin? Am J Geriatr Pharmacother. 2005 Dec;3(4):274-87. Review.</citation>
    <PMID>16503325</PMID>
  </reference>
  <results_reference>
    <citation>Nissman SA, Tractenberg RE, Babbar-Goel A, Pasternak JF. Oral gabapentin for the treatment of postoperative pain after photorefractive keratectomy. Am J Ophthalmol. 2008 Apr;145(4):623-629. doi: 10.1016/j.ajo.2007.11.012. Epub 2008 Jan 28.</citation>
    <PMID>18226799</PMID>
  </results_reference>
  <results_reference>
    <citation>Dauri M, Faria S, Gatti A, Celidonio L, Carpenedo R, Sabato AF. Gabapentin and pregabalin for the acute post-operative pain management. A systematic-narrative review of the recent clinical evidences. Curr Drug Targets. 2009 Aug;10(8):716-33. Review.</citation>
    <PMID>19702520</PMID>
  </results_reference>
  <results_reference>
    <citation>Jokela R, Ahonen J, Tallgren M, Haanpää M, Korttila K. Premedication with pregabalin 75 or 150 mg with ibuprofen to control pain after day-case gynaecological laparoscopic surgery. Br J Anaesth. 2008 Jun;100(6):834-40. doi: 10.1093/bja/aen098. Epub 2008 Apr 29.</citation>
    <PMID>18448418</PMID>
  </results_reference>
  <results_reference>
    <citation>Paech MJ, Goy R, Chua S, Scott K, Christmas T, Doherty DA. A randomized, placebo-controlled trial of preoperative oral pregabalin for postoperative pain relief after minor gynecological surgery. Anesth Analg. 2007 Nov;105(5):1449-53, table of contents.</citation>
    <PMID>17959981</PMID>
  </results_reference>
  <results_reference>
    <citation>Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesth Analg. 2007 Jun;104(6):1545-56, table of contents. Review.</citation>
    <PMID>17513656</PMID>
  </results_reference>
  <results_reference>
    <citation>Blake CR, Cervantes-Castañeda RA, Macias-Rodríguez Y, Anzoulatous G, Anderson R, Chayet AS. Comparison of postoperative pain in patients following photorefractive keratectomy versus advanced surface ablation. J Cataract Refract Surg. 2005 Jul;31(7):1314-9.</citation>
    <PMID>16105600</PMID>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>June 21, 2010</last_update_submitted>
  <last_update_submitted_qc>June 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Capt Julie Meek</name_title>
    <organization>Wilford Hall Medical Center, US Air Force</organization>
  </responsible_party>
  <keyword>photorefractive keratectomy</keyword>
  <keyword>excimer laser</keyword>
  <keyword>PRK</keyword>
  <keyword>pain, postoperative</keyword>
  <keyword>pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

